Transforming medicine with novel early stage therapies that eliminate disease-causing proteins #proteindegradation
Location: United States, Massachusetts, Watertown
Employees: 51-200
Total raised: $243M
Founded date: 2016
Investors 8
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.06.2020 | - | $170M | - |
| 07.01.2016 | Series A | $73M | - |
Mentions in press and media 12
| Date | Title | Description |
| 25.11.2024 | Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) | New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of private plac... |
| 06.09.2024 | Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) | New York, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered ... |
| 05.03.2024 | C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024 | - |
| 24.05.2021 | Eliem Therapeutics Announces $60 Million Series B Financing | |
| 24.05.2021 | Eliem Therapeutics, Inc. announced that it has received $60 million in funding from Intermediate Capital Group plc, RA Capital Management, L.P., Access Biotechnology, Samlyn Capital, LLC, Acorn Bioven... | On May 24, 2021, Eliem Therapeutics, Inc. closed the transaction. The company announced that it has received $60,000,000 in its series B round of funding co-led by returning investors RA Capital Management, L.P. and Intermediate Capital Gro... |
| 19.10.2020 | ONK Therapeutics Closes US$8M Financing | ONK Therapeutics Ltd, a Galway, Ireland-based natural killer (NK) cell therapy company, raised US$8M in financing. This round, which brought the total raised in the last six months to US$14.6M, was led by Acorn Bioventures, and current shar... |
| 17.06.2020 | C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept and to Advance Proprietary Platform | - |
| 16.06.2020 | C4 Therapeutics Raises $170M in Funding | C4 Therapeutics, Inc., a Watertown, Mass.-based biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, closed a $170m financing. This included $150m in Series ... |
| 04.01.2019 | Joining forces with Skyhawk, C4 Therapeutics, Biogen buys more shots on goal on SMA, Alzheimer's | These days at Biogen, the spotlight tends to fall on one of two programs: Its commercial SMA drug Spinraza, and the experimental Alzheimer’s therapy aducanumab — and its dealmaking team knows it. Michael Ehlers In twin deal... |
| 04.01.2018 | Pfizer and Arvinas sign $830M drug development deal that target proteins causing disease | So what’s attracting the big fish? There are no clinical programs tied up in any of the deals. Instead, they will be drawing on the fruits of Arvinas’s proprietary PROteolysis TArgeting Chimeras (PROTAC) platform. According to a company spo... |
Show more